Symmetry Partners LLC Lowers Position in Eli Lilly and Company $LLY

Symmetry Partners LLC reduced its stake in Eli Lilly and Company (NYSE:LLY) by 1.0% during the second quarter, Holdings Channel.com reports. The firm owned 1,939 shares of the company’s stock after selling 20 shares during the period. Symmetry Partners LLC’s holdings in Eli Lilly and Company were worth $1,512,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Grandview Asset Management LLC boosted its position in shares of Eli Lilly and Company by 3.4% during the second quarter. Grandview Asset Management LLC now owns 1,417 shares of the company’s stock valued at $1,105,000 after purchasing an additional 46 shares in the last quarter. Sonora Investment Management Group LLC lifted its holdings in shares of Eli Lilly and Company by 5.6% during the second quarter. Sonora Investment Management Group LLC now owns 3,220 shares of the company’s stock valued at $2,510,000 after purchasing an additional 170 shares in the last quarter. Fort Washington Investment Advisors Inc. OH lifted its holdings in shares of Eli Lilly and Company by 1,266.5% during the second quarter. Fort Washington Investment Advisors Inc. OH now owns 34,614 shares of the company’s stock valued at $26,983,000 after purchasing an additional 32,081 shares in the last quarter. WD Rutherford LLC bought a new position in shares of Eli Lilly and Company during the second quarter valued at $86,000. Finally, Clay Northam Wealth Management LLC increased its position in Eli Lilly and Company by 6.2% during the second quarter. Clay Northam Wealth Management LLC now owns 258 shares of the company’s stock valued at $201,000 after acquiring an additional 15 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $724.73 on Friday. The firm has a market cap of $685.93 billion, a PE ratio of 47.37, a PEG ratio of 1.01 and a beta of 0.47. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $937.00. The stock has a 50 day moving average of $734.15 and a 200 day moving average of $766.82. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company’s revenue for the quarter was up 37.6% on a year-over-year basis. During the same period last year, the company earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on LLY shares. Berenberg Bank reissued a “hold” rating and set a $830.00 price target (down previously from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Deutsche Bank Aktiengesellschaft dropped their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Erste Group Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Finally, HSBC raised Eli Lilly and Company from a “reduce” rating to a “hold” rating and upped their price objective for the stock from $675.00 to $700.00 in a research note on Wednesday, August 27th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $939.61.

Insiders Place Their Bets

In other news, Director J Erik Fyrwald acquired 1,565 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares of the company’s stock, valued at $47,903,686.74. This trade represents a 2.14% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO David A. Ricks acquired 1,632 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the acquisition, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.